Barinthus Bio Announces Strategic Pipeline Prioritization Following Positive Interim Data from VTP-300 in Chronic Hepatitis B Virus Infections
June 12, 2024 16:01 ET
|
Barinthus Biotherapeutics
Barinthus Bio Announces Strategic Pipeline Prioritization Following Positive Interim Data from VTP-300 in Chronic Hepatitis B Virus Infections
Azuria Announces Acquisition of Infrastructure Services Group LLC and Subsidiaries
June 11, 2024 10:36 ET
|
Azuria Water Solutions
Azuria Announces Acquisition of Infrastructure Services Group LLC and Subsidiaries
AUROBAC THERAPEUTICS Presents its R&D Strategy & Pipeline and Announces New Development Program in Partnership with Boehringer Ingelheim
June 03, 2024 08:14 ET
|
AUROBAC THERAPEUTICS
AUROBAC THERAPEUTICS to advance ATX101 in septic shock, and multiple preclinical and discovery programs targeting Gram-negative pathogens. Lyon (France), June 3, 2024 AUROBAC THERAPEUTICS, a...
Mural Oncology Presents Clinical Data from ARTISTRY-3 at the American Society of Clinical Oncology Annual Meeting
May 23, 2024 17:00 ET
|
Mural Oncology, Inc.
ARTISTRY-3 trial is being conducted to evaluate less frequent dosing of nemvaleukin alfa, Mural’s late-stage lead candidate Nemvaleukin demonstrated pharmacodynamic proof of mechanism in ARTISTRY-3...
Mural Oncology Announces First Quarter 2024 Financial Results and Provides Business Update
May 14, 2024 07:00 ET
|
Mural Oncology, Inc.
Mural Oncology reiterates cash runway projection into 4Q 2025, with sufficient capital to fund key clinical readouts.
Aegion Rebrands as Azuria Water Solutions, Signaling a New Era in Water Infrastructure Solutions
April 25, 2024 13:58 ET
|
Azuria Water Solutions
Aegion Corporation today announced its official rebrand to Azuria Water Solutions, the leading provider of technology-enabled products and services.
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
April 16, 2024 04:35 ET
|
Boehringer Ingelheim
Human Pharma sales up 10.3%* to EUR 20.8 bn, driven by JARDIANCE® and OFEV®Animal Health sales up 6.9 %* to EUR 4.7 bn, fueled by new product launchesR&D expenditures increase by 14.2% to EUR 5.8...
Tevogen Bio’s Chief Scientific Officer Speaks on the Harnessing of Cytotoxic T Lymphocytes (CTLs) to Target Cancers
April 11, 2024 08:05 ET
|
Tevogen Bio Inc
Tevogen’s Chief Scientific Officer explains the company’s oncology pipeline strategy as it relates to harnessing Cytotoxic T Lymphocytes to target cancers.
Mural Oncology Presents Preclinical Data for IL-18 and IL-12 Programs at the 2024 American Association for Cancer Research Annual Meeting
April 09, 2024 16:00 ET
|
Mural Oncology, Inc.
Mural Oncology, a clinical-stage immuno-oncology company, shared pre-clinical data from its Interleukin-18 (IL-18) and IL-12 programs at AACR today.
Aegion Announces Acquisition of Toncco
March 27, 2024 11:00 ET
|
Aegion Corp
Aegion Corporation today announced the acquisition of Toncco, an underground utilities company based in Ogden, Utah.